Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Creatv Microtech Inc. maintains a portfolio with 5 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners and 5 distinct art units. This one-to-one ratio between actions, examiners, and art units indicates a diverse set of filings that are being reviewed independently across different specialized groups at the USPTO.
The busiest examiner for the company is NGUYEN, NGHI V, who is currently managing 1 pending office action. This distribution suggests that no single examiner's tendencies will dominate the outcomes for the 5 pending office actions. The workload is spread such that each individual is currently managing exactly one action.
With 5 distinct art units involved, the company must tailor its technical arguments to the specific nuances of different regulatory environments within the Biotechnology & Pharmaceuticals sector. The presence of 5 distinct examiners means the legal team must manage multiple professional relationships, including the one with NGUYEN, NGHI V, to address the current workload.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| LANDAU, SHARMILA GOLLAMUDI | 1 | 11.1% | +4.6% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| PHAM, THOMAS T | 1 | 51.4% | +15.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430457 | CCR5-BASED METHODS FOR PREDICTING OVERALL AND PROGRESSION FREE SURVIVAL IN SUBJECTS HAVING CANCER | STONEBRAKER, ALYSSA RAE | 4d overdue |
| 18580301 | METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS) | NGUYEN, NGHI V | — |
| 17509661 | CAPTURE, IDENTIFICATION AND USE OF A NEW BIOMARKER OF SOLID TUMORS IN BODY FLUIDS | LANDAU, SHARMILA GOLLAMUDI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430457 | CCR5-BASED METHODS FOR PREDICTING OVERALL AND PROGRESSION FREE SURVIVAL IN SUBJECTS HAVING CANCER | STONEBRAKER, ALYSSA RAE | 4d overdue |
| 16265305 | Fabrication of Microfilters and Nanofilters and Their Applications | PHAM, THOMAS T | 28d |
| 18580301 | METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS) | NGUYEN, NGHI V | — |
| 17128807 | USE OF CIRCULATING CELL BIOMARKERS IN THE BLOOD FOR DETECTION AND DIAGNOSIS OF DISEASES AND METHODS OF ISOLATING THEM | NGUYEN, NAM P | — |
| 16979742 | METHODS FOR MONITORING TREATMENT RESPONSE AND DISEASE PROGRESSION IN SUBJECTS USING CIRCULATING CELLS | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1653 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| 1646 | 1 |
| 1713 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580301 | METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS) | NGUYEN, NGHI V | 1657 | §101§102DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 17509661 | CAPTURE, IDENTIFICATION AND USE OF A NEW BIOMARKER OF SOLID TUMORS IN BODY FLUIDS | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103 | Final Rejection | — | Pending | Oct 25, 2021 |
| 17430457 | CCR5-BASED METHODS FOR PREDICTING OVERALL AND PROGRESSION FREE SURVIVAL IN SUBJECTS HAVING CANCER | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | 4d overdue | Pending | Aug 12, 2021 |
| 17128807 | USE OF CIRCULATING CELL BIOMARKERS IN THE BLOOD FOR DETECTION AND DIAGNOSIS OF DISEASES AND METHODS OF ISOLATING THEM | NGUYEN, NAM P | 1678 | §103DP | Final Rejection | — | Pending | Dec 21, 2020 |
| 16979742 | METHODS FOR MONITORING TREATMENT RESPONSE AND DISEASE PROGRESSION IN SUBJECTS USING CIRCULATING CELLS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Other | Final Rejection | — | Pending | Sep 10, 2020 |
| 16265305 | Fabrication of Microfilters and Nanofilters and Their Applications | PHAM, THOMAS T | 1713 | §103 | Final Rejection | 28d | Pending | Feb 01, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial